Acomplia News

A promising piece of Acomplia news from JDPGlobal. JDPGlobal news reported that market analysts predict a 1.7 billion dollar growth in the market for weight loss pills by 2014. One reason for this predicted growth is the expected popularity of the new diet pill Acomplia, manufactured by Sanofi Aventis. Final FDA approval for the new drug is expected shortly in the United States.

With obesity now considered a worldwide problem, or pandemic, the market for pharmaceuticals to treat seriously overweight people will undoubtedly continue to grow. If Acomplia is as effective as its many backers believe it will be, sales of the new drug may claim more than half of the entire weight loss drug market in the next several years.

The weight loss drug market is presently a relatively small one compared to the market for other drugs. This is partly because overweight people do not tend to seek medical attention and because many insurance plans to not cover weight loss pills. Also, negative publicity in the past about weight loss drugs such as Fen-Phen may discourage consumers from trying diet pills.

However, with its potential array of positive effects, Acomplia is in a position to change people’s thinking about diet pills. It is the first weight loss pill that also has the potential to treat symptoms of cardiovascular disease and metabolic function associated with being overweight. Acomplia’s apparent ability to lower triglycerides and levels of HDL cholesterol as well as increase insulin sensitivity make it more than an ordinary appetite suppressant. Improvements in these measures in people who take Acomplia are thought to be more significant than the improvements that would occur simply from losing weight, meaning that the results can be attributed to the drug, not just to the fact that a person has lost weight.

Some more good news for the customers

Another good Acomplia news. A study released in February 2006 and reported in the Journal of the American Medical Association showed that people who were successful in losing weight with Acomplia were able to keep the weight off for at least two years. This gives Acomplia a further edge over other weight loss pills, such as Meridia (sibutramine) and Xenical (orlistat).

The manufacturer of Acomplia, Sanofi-Aventis, says that the study is consistent with other studies that produced similar results. In all of these studies, subjects taking Acomplia also saw improvements in a number of cardiometabolic markers, including lower levels of blood sugar, cholesterol, triglycerides and blood pressure in addition to a reduction in body weight and waist circumference. Other factors that seem to improve with Acomplia include markers of inflammation that may be associated with an increased risk for heart disease. These markers are known as adiponectin and C-reactive protein (CRP).